Skip to content

Study of the correlation between blood, urine and fecal proteomics and vaccine response after vaccination with COVID-19 vaccine

Study of the correlation between blood, urine and fecal proteomics and vaccine response after vaccination with COVID-19 inactivated vaccine

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044919
Enrollment
Unknown
Registered
2021-03-31
Start date
2021-02-01
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

WESTLAKE UNIVERSITY
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 60 years; 2. All the included populations voluntarily receive the new crown vaccination and voluntarily join the study; 3. Healthy volunteers who meet the requirements for vaccination.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to any ingredient in the vaccine; 2. Those who have experienced severe allergic reactions to vaccines in the past, such as acute allergic reactions, urticaria, skin eczema, dyspnea, angioedema or abdominal pain; 3. People with fever, severe acute disease, acute attack of chronic disease; 4. Those who have recovered from new coronary pneumonia or asymptomatic infection; 5. Couples who have a family plan within 3 months of vaccination, as well as pregnant women and lactating women; 6 People with history or family history of convulsions, epilepsy, encephalopathy or mental illness; 7. People with uncontrolled epilepsy and other progressive neurological diseases, and those with a history of Guillain-Barré syndrome; 8. Has been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases; 9. Those who are known or suspected of suffering from severe respiratory diseases, severe cardiovascular diseases, liver and kidney diseases, and malignant tumors; 10. Those who use immunomodulators such as anti-tumor drugs; 11. Those who are deemed unsuitable for vaccination by clinicians or vaccination staff; 12. The vaccinators who refused to join this study; 13. Those who withdrew from the study without any reason iduring the study.

Design outcomes

Primary

MeasureTime frame
Serum IgG;Serum IgM;Proteinomics(blood, urine and fecal);T cell immune subgroup;Neutralizing antibody;

Secondary

MeasureTime frame
Inflammation markers;

Countries

China

Contacts

Public ContactYang Shiming

Xinqiao Hospital, Army Military Medical University

Yangshiming@tmmu.edu.cn+86 23 68755604

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026